Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
10%
Atezolizumab
58%
Beta Adrenergic Receptor Blocking Agent
12%
Bevacizumab
9%
Bioavailability
15%
Breast Cancer
17%
C Reactive Protein
9%
Capsule
9%
Clarithromycin
8%
Clinical Trial
25%
Combination Therapy
26%
Controlled Release Formulation
17%
Depression
17%
Disease Activity
16%
Disease Modifying Antirheumatic Drug
17%
Dissolution
20%
Drug
38%
Drug Absorption
26%
Drug Interaction
10%
Drug Release
9%
Esophagus Cancer
8%
Etoposide
8%
Fluorouracil
8%
Hydroxyitraconazole
17%
Immune Checkpoint Inhibitor
12%
Immunotherapy
17%
Itraconazole
26%
Lipid
12%
Lung Cancer
17%
Malignant Neoplasm
27%
Non Small Cell Lung Cancer
18%
NONMEM
11%
Normal Human
30%
Obesity
10%
Overall Survival
20%
Oxycodone
17%
Paclitaxel
10%
Pharmacodynamics
17%
Pharmacokinetic Modeling
19%
Pharmacokinetics
100%
Proton Pump Inhibitor
10%
Remission
30%
Rheumatoid Arthritis
43%
Sex Hormone
8%
Silicon Dioxide
8%
Survival
19%
Sustained Release
10%
Tablet
19%
Tolerability
8%
Ultra High Performance Liquid Chromatography
8%
Medicine and Dentistry
Accuracy
8%
Adverse Event
9%
Analysis
27%
Anxiety
8%
Association
40%
Atezolizumab
32%
Beta Adrenergic Receptor Blocking Agent
8%
Bevacizumab
9%
Body Mass Index
10%
C Reactive Protein
18%
Cells
8%
Chemoimmunotherapy
8%
Clear Cell Renal Cell Carcinoma
8%
Clinical Disease Activity Index
7%
Clinical Trial
6%
Combination Therapy
26%
Depression
8%
Disease Modifying Antirheumatic Drug
17%
Enalapril Maleate
6%
Female
10%
Hepatocellular Carcinoma
8%
Immune Checkpoint Inhibitor
7%
Immunotherapy
10%
Inpatient
52%
Learning
18%
Lung
8%
Lung Cancer
17%
Non Small Cell Lung Cancer
12%
Obesity
8%
Oncology
11%
Overall Survival
33%
Patient
64%
Patient-Reported Outcome
26%
Pooled Analysis
10%
Post-Hoc Analysis
8%
Progression Free Survival
11%
Proportional Hazards Model
8%
Proton-Pump Inhibitor
8%
Rheumatoid Arthritis
35%
Sex Hormone
8%
Simplified Disease Activity Index
8%
Skin Cancer
8%
Spontaneous Remission
29%
Subgroup Analysis
8%
Survival
37%
Syndrome
8%
Therapeutic Procedure
38%
Tocilizumab
16%
Transitional Cell Carcinoma
17%
Urothelial Cancer
8%
Nursing and Health Professions
Analysis
28%
Antihypertensive Agent
8%
Atezolizumab
22%
Breast Cancer
8%
Combination Therapy
10%
Depression
8%
Diseases
9%
Drug Therapy
9%
Hospital Mortality
8%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
8%
Lung Cancer
17%
Malignant Neoplasm
12%
Meta Analysis
8%
Monkeypox
8%
Morbidity
8%
Overall Survival
11%
Patient
8%
Patient with Cancer
8%
Patient-Reported Outcome
18%
Rheumatoid Arthritis
8%
Survival
18%
Systematic Review
8%
Treatment Outcome
8%
